Regenerate. Repair. Restore.

Stem Cells Therapy for Alzheimers Disease and neurodegeneration

Neurodegeneration is the progressive loss of structure and/or function of neurons including death. Neurodegenerative diseases include; Alzheimer’s disease, Parkinson’s disease and Huntington’s disease.

Alzheimer’s disease (AD) is the most common cause of dementia and is responsible for 60-80 percent of dementia cases.

The Stem Cells Transplant Institute recommends the use of mesenchymal stem cells, derived cultured, and expanded from umbilical cord tissue, for the treatment of neurological diseases including Alzheimer’s disease.

Treatment at the Stem Cells Transplant Institute could help improve the symptoms of Alzheimer’s disease including:

  • Forgetfulness
  • Confusion
  • Mood swings
  • Distrust in others
  • Changes in sleeping habits
  • Depression
  • Irritability and aggressiveness
  • Wandering
  • Apathy
  • Social withdrawal

What is Alzheimer’s disease?

Dementia is a fatal disease characterized by chronic inflammation and neuronal loss resulting in amnesia, progressive cognitive impairment, and disorientation.

Alzheimer’s disease is the most common form of dementia with more than 5 million people in the United States living with this devastating disease, and it is the 6th leading cause of death, killing more people than prostate cancer and breast cancer combined.1.

The exact cause of Alzheimer’s disease is unknown but there are four key features; 1. Amyloid-beta (Aß) plaques, 2. Neurofibrillary tangles, 3. Neuroinflammation, and 4. Mass neuronal and synaptic loss. Amyloid-beta plaques are sticky clumps of protein fragments that accumulate and attack brain cells, leading to their death. Neurofibrillary tangles are twisted fibers of Tau protein that build up inside the neurons of Alzheimer’s patients damaging neural structures and inhibiting the transport of nutrients. Neuroinflammation is caused by the activation of microglia which mediate immune responses. Microglia are activated and begin producing cytokines that increase neuroinflammation. All of these factors result in mass neuronal and synaptic loss causing the cortex region of the brain to atrophy, or decrease in size.3-7

Eventually, Alzheimer’s kills, but not before It takes everything away from you.

-Alzheimer’s Association

How can stem cell therapy improve the symptoms of Alzheimer’s disease?

Human umbilical cord mesenchymal stem cells (hUC-MSCs) can promote the release of acetylcholine, promote neurogenesis and synaptic formation and can reduce oxidative stress and cell death. Research is showing hUC-MSCs to be a better alternative to allogeneic stem cells because of their hypo-immunogenicity, superior tropism, high differentiation potential and paracrine activity.10-13

Evidence suggests HUC-MSCs can differentiate into a variety of neuro-regulatory molecules and can elevate several factors including brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), insulin-like growth factor 1 (IGF-1), Glucagon-like pepetide-1 (GLP-1), and vascular endothelial growth factor (VEGF).9

Neural stem cells transplanted at sites of nerve injury are thought to promote functional recovery by producing trophic factors that induce survival and regeneration of host neurons. Intravenously administered mesenchymal stem cells are also capable of crossing the blood-brain barrier and effectively migrating to regions of neural injury, without inducing tumor growth or an immune response.9

Research has shown mesenchymal stem cells have the potential to affect Alzheimer’s through multiple pathways and can:

  • Decrease Amyloid-beta plaque formation
  • Stimulate neurogenesis, synaptogenesis and neuronal differentiation
  • Rescue spatial learning and memory deficits
  • Possibly decrease inflammation by upregulating neuroprotective cytokines and decreasing pro-inflammatory cytokines

According ClinicalTrials.gov (https://clinicaltrials.gov) on March 18, 2019, the safety and efficacy results from animal models has led to the following five trials evaluating the safety and efficacy of hUC-MSC transplantation in patients diagnosed with Alzheimer’s disease.

Title

Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC) in Patients With Alzheimer’s Disease

Study Results

No Results Available

Conditions

Alzheimer’s Disease

Interventions

Biological: Human Umbilical Cord Derived MSC

Title

Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer’s Disease

Study Results

No Results Available

Conditions

Alzheimer’s Disease

Interventions

Biological: UCMSCs Biological: Placebo

Title

The Safety and The Efficacy Evaluation of NEUROSTEM®- AD in Patients With Alzheimer’s Disease

Study Results

Published14

Conditions

Dementia of the Alzheimer’s type

Interventions

Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells

Title

Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer’s Disease

Study Results

No Results Available

Conditions

Alzheimer’s Disease

Interventions

Biological: human umbilical cord blood derived mesenchymal stem cells
Other: Normal saline 2mL

Title

Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.

Study Results

No Results Available

Conditions

Alzheimer’s Disease

Interventions

Biological: human umbilical cord blood derived mesenchymal stem cells Other: Normal saline 2mL

What is the treatment protocol for Alzheimer’s disease at the Stem Cells Transplant Institute?

The Stem Cells Transplant Institute recommends the use of hUC-MSCs for the treatment of Alzheimer’s disease. For optimal results, we recommend Aggressive Platinum Therapy (APT). APT is a 4-day treatment plan.

Each day you will receive the following:

  • 120 million mesenchymal stem cells (MSC) cultured and expanded from human umbilical cord tissue for a 4-day total of 480 million MSCs.
  • Antioxidant therapy with vitamin C and glutathione
  • Ozone therapy
  • Platelet-rich plasma therapy (PRP)

What are the advantages of human umbilical cord mesenchymal stem cells?​

  • Abundant supply containing up to 10 times more stem cells than bone marrow or adipose derived stem cells
  • hUC-MSC have immunosuppressors and immunomodulatory properties that allow their use in any individual without rejection- Human Leukocyte Antigen (HLA) matching is not necessary
  • Greater proliferation ability than adult autologous stem cells
  • They regenerate at a very rapid rate
  • They are young and very adaptive
  • They have not been impacted by the aging process
  • They have not been affected by environmental toxins
  • Umbilical cord stem cells can be administered multiple times over the course of days
  • Eliminates the need to collect stem cells from the patient’s fat or hip bone reducing pain and recovery time

 

What are the challenges?

Alzheimer’s disease destroys many different types of neurons in the brain.Successful treatment requires all the stem cells to travels to and differentiate into different types of neurons and other brain cells correctly.At this time stem cell therapy does not stop the underlying cause of Alzheimer’s disease and patient may need more than one treatment due to a declining effect over time

umbilical cord donations
Intravenus Administration

How Are the Stem Cells Collected?

Our clinic focuses on obtaining healthy stem cells exclusively from umbilical cord blood donors. We collect the placenta once the baby is born, with the parent’s informed consent. Additionally, we follow strict ethical guidelines and collect stem cells from reliable and reputable sources.

How Are the Stem Cells Administered?

Our nursing staff administers the stem cells through an intravenous and intra-pulmonary route. For the most effective outcomes, intravenous administration is preferred.

About the Stem Cells Transplant Institute

Our clinic is located in Costa Rica, which is one of the most popular medical tourism destinations for stem cell therapy. At the Stem Cells Transplant Institute, we have a skilled team of doctors and medical professionals who collect and administer stem cells to treat autism and other conditions. Every patient receives the most cost-effective and top-notch care from our dedicated team.

Scientific References:

  1. Alzheimer’s Association. 2017 Alzheimer’s Disease Facts and Figures. Alzheimer’s Dement 2017;13:325-373.
  2. Tang Jun, How close is the stem cell cure to the Alzheimer’s disease: Future and Beyond? Neural Regen Res. 2012 Jan 5; 7(1): 66–71.
  3. Thomas Duncan and Michael Valenzuela. Alzheimer’s disease, dementia and stem cell therapy. Stem Cell Research & Therapy (2017) 8:111.
  4. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M,Honig LS, Porsteinsson AP, Ferris S. Two phase 3 trials of bapineuzumab inmild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–33.
  5. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F,Sun X, Thomas RG. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369:341–50.
  6. Walker D, Lue LF. Investigations with cultured human microglia onpathogenic mechanisms of Alzheimer’s disease and other neurodegenerative diseases. J Neurosci Res. 2005;81:412–25.
  7. Delbeuck X, Van der Linden M, Collette F. Alzheimer’s disease as a disconnection syndrome? Neuropsychol Rev. 2003;13:79–92.
  8. Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, Kim YJ, Jo JY, Yoon EJ, Choi HJ. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011;20:1297–308.
  9. Fang Y, Gao T, Zhang B, Pu J. Recent Advances: Decoding Alzheimer’s Disease With Stem Cells. Front Aging Neurosci. 2018;10:77. Published 2018 Mar 22. doi:10.3389/fnagi.2018.00077
  10. Dong Hyun Kim et. al., Thrombospondin-1 secreted by human umbilical cord blood-derived mesenchymal stem cells rescues neurons from synaptic dysfunction in Alzheimer’s disease model. Scientific Reports volume8, Article number: 354 (2018) 
  11. Lee, M. et al. Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitroand in vivoBiochem Biophys Res Commun446, 983–9 (2014).
  12. Kim, J. Y., Jeon, H. B., Yang, Y. S., Oh, W. & Chang, J. W. Application of human umbilical cord blood-derived mesenchymal stem cells in disease models. World J Stem Cells2, 34–8 (2010).
  13. Jeong, S. Y. et al. Thrombospondin-2 secreted by human umbilical cord blood-derived mesenchymal stem cells promotes chondrogenic differentiation. Stem Cells31, 2136–48 (2013).
  14. Kim HJ, Seo SW, Chang JW, Lee JI, Kim CH, Chin J, Choi SJ, Kwon H, Yun HJ, Lee JM, Kim ST, Choe YS, Lee KH, Na DL. Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: A phase 1 clinical trial. Alzheimers Dement (N Y). 2015 Jul 26;1(2):95-102. doi: 10.1016/j.trci.2015.06.007. eCollection 2015 Sep.